Prior to transitioning, both rheumatologists and their patients must be fully informed about the policy requiring the transition and have all available information about the biosimilar, such as details about safety and efficacy, the reimbursement policy, patient program information, including contact names and phone numbers. Having this information can also ensure patients and rheumatologists have an informed and constructive conversation about why a patient’s treatment is being changed.

During the first conversations about transitioning to a biosimilar, the way in which rheumatologists and other health care providers communicate with patients is key to ensuring a patient’s positive expectations and a smooth transition to the new treatment.

In this video, we present an example of a positive rheumatologist-patient biosimilars transition conversation.